Connect drug reduces COPD attacks 85%, misses a secondary goal
Connect drug reduces COPD attacks 85%, misses a secondary goal
Connect Biopharma
NASDAQ: CNTB $0.93 USD
Clinical-stage biopharmaceutical company developing therapies for T cell-driven inflammatory diseases, led by rademikibart (CBP-201), an IL-4R alpha antibody in late-stage development for atopic dermatitis, asthma and COPD.
Company Info
Sector:Biopharmaceuticals
Headquarters:San Diego, California, USA
Founded:2012
Website:www.connectbiopharma.com/